Heng Mei

Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma

Data on long-term outcomes of in vivo chimeric antigen receptor T cell (CAR‑T) therapy remain scarce. We previously reported preliminary safety and efficacy data of in vivo B-cell maturation antigen (BCMA) CAR‑T (ESO-T01), in four patients with relapsed/refractory multiple myelom...

Machine Learning-Based Prediction of Mononuclear Cell Collection Efficiency for CAR-T Manufacturing

Abstract Objective To develop and internally validate an interpretable machine-learning model using routine precollection variables to predict mononuclear cell (MNC) collection efficiency (CE) during leukapheresis for CAR-T manufacturing. Methods This retrospective study included...